title: Assessment of Parkinson disease: what do we need to show neuroprotection?
abstract: To date, no pharmacological agent has convincingly demonstrated the ability to slow the progression of Parkinson disease (PD). The development of treatments that slow down the progressive degeneration of the nigrostriatal dopaminergic system (true neuroprotection), which is ultimately responsible for the patients' functional decline, has become one of the basic goals of PD research. In this review, we have attempted to analyze the role of different methods that measure PD severity (basically, clinical scales, timed tests, and neuroimaging techniques) in the evaluation of the "neuroprotection" provided by different types of treatment for the disease, on the basis of clinical evidence.
authors: Department of Neurology, Hospital Universitario La Paz, Madrid, Spain.
authors: Isabel
authors: I
authors: Ybot-Gorrin
authors: Francisco
authors: F
authors: Vivancos-Matellano
authors: José Rafael
authors: JR
authors: Chacón-Peña
authors: Hortensia
authors: H
authors: Alonso-Navarro
authors: Félix Javier
authors: FJ
authors: Jiménez-Jiménez
mesh_terms: D000203:Activities of Daily Living; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D059906:Neuroimaging / Q000379:methods; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology*
chemical_list: D018696:Neuroprotective Agents